Vice Chairman of Political Consultative Conference of Wenzhou Ouhai District Visited Jiangsu Vcare

Jiangsu Vcare's New-generation TRK Inhibitor VC004 Obtains IND Approval from the US FDA

On October 16, 2024, Jiangsu Vcare Pharmatech Co., Ltd. (referred to as "Jiangsu Vcare")'s independently developed new-generation anti-resistant TRK inhibitor VC004 achieved a significant milestone progress, and the project officially obtained the Investigational New Drug (IND) permission from the US Food and Drug Administration (FDA). This fully demonstrates Jiangsu Vcare's excellent drug research and development capabilities and is a successful practice of the company's strategies based on original innovation, high-quality standards, and a global layout.

View Details

Jiangsu Vcare’s Next-Generation TRK Inhibitor VC004 IND Application was accepted by the US FDA

At the end of September 2024, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that the US FDA has officially accepted the Investigational New Drug (IND) application of its independently developed new-generation anti-resistant TRK inhibitor VC004. This milestone paves the way for the global commercialization strategy.

View Details

Jiangsu Vcare Pharmatech Co., Ltd. Selected as National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises

Recently, the Ministry of Industry and Information Technology (MIIT) announced the sixth batch of National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises, andJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) was successfully selected. Thisnational-levelhonor fully demonstrates that under its "dual-core business model," Jiangsu Vcare's scientific research capabilities, independent innovation capacity, market leadership, and future development potential have received official high recognition.

View Details

Jiangsu Vcare Announces Successfully Unblinding of VC005 Topical Gel Clinical Phase I Data

Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the successful unblinding of Phase I clinical data for its self-developed VC005 gel, a second-generation selective JAK1 inhibitor, in the topical treatment of mild-to-moderate atopic dermatitis (AD). The results demonstrated exceptional safety and significant efficacy.

View Details

Jiangsu Vcare's VC005 has Achieved Positive Topline Data in the Phase II Clinical Trial for the Oral Treatment of Atopic Dermatitis

Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced positive topline data from its Phase II clinical trial of VC005 tablets, a second-generation selective JAK1 inhibitor, for the oral treatment of moderate-to-severe atopic dermatitis (AD).

View Details

Announcement on Company Name Change by Jiangsu Vcare Pharmatech Co., Ltd.

July 12, 2024, Jiangsu Vcare Pharmatech Co., Ltd. (hereinafter referred to as "the Company") has completed the industrial and commercial registration for its name change and obtained the renewed Business License issued by the Administrative Approval Bureau of Nanjing Jiangbei New Area.

View Details